CORRESP Filing
bioAffinity Technologies, Inc.
Date: April 16, 2025 · CIK: 0001712762 · Accession: 0001641172-25-005116
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286497
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Margaret Sawicki bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed April 11, 2025 File No: 333-286497
Dear Ms. Sawicki:
bioAffinity Technologies, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-286497), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Friday, April 16, 2025 , at 5:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow or Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Leslie Marlow at (212) 885-5358 or Melissa Palat Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very
truly yours,
BIOAFFINITY
TECHNOGIES, INC.
Show Raw Text
CORRESP 1 filename1.htm April 16, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Sawicki Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed April 11, 2025 File No: 333-286497 Dear Ms. Sawicki: bioAffinity Technologies, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-286497), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Friday, April 16, 2025 , at 5:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter. The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes Leslie Marlow or Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Leslie Marlow at (212) 885-5358 or Melissa Palat Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted. Very truly yours, BIOAFFINITY TECHNOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: Chief Executive Officer cc: Leslie Marlow, Blank Rome LLP Melissa Palat Murawsky, Blank Rome LLP